Details for: IMPDH2
Gene ID: 3615
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: IMPDH2
Ensembl ID: ENSG00000178035
Description: inosine monophosphate dehydrogenase 2
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 80.67rCSI 53.62%PRS 81.34
-
CSI 75.61rCSI 61.14%PRS 80.7
-
CSI 69.86rCSI 63.09%PRS 76.64
-
CSI 61.25rCSI 53.04%PRS 82.55
-
CSI 56.68rCSI 54.65%PRS 71.46
-
CSI 56.27rCSI 47.17%PRS 81.53
-
CSI 53.83rCSI 56.26%PRS 76.01
-
CSI 50.65rCSI 44.49%PRS 83.41
-
CSI 47.22rCSI 55.46%PRS 80.06
-
CSI 39.85rCSI 45.62%PRS 89.09
-
CSI 39.55rCSI 49.64%PRS 87.16
-
CSI 36.2rCSI 52.21%PRS 84.48
-
CSI 31.43rCSI 26.06%PRS 78.94
-
CSI 31.02rCSI 61.49%PRS 83.96
-
CSI 29.09rCSI 28%PRS 77.7
-
CSI 27.5rCSI 39.25%PRS 79.33
-
CSI 27.2rCSI 36.34%PRS 92.58
-
CSI 26.38rCSI 38.02%PRS 85.4
-
CSI 24.25rCSI 25.4%PRS 75.82
-
CSI 24.01rCSI 89.96%PRS 70.74
-
CSI 23.21rCSI 27.86%PRS 76.01
-
CSI 22.88rCSI 34.99%PRS 87.03
-
CSI 22.12rCSI 62.87%PRS 74.67
-
CSI 21.46rCSI 17.77%PRS 80.96
-
CSI 20.95rCSI 27.84%PRS 84.09
-
CSI 20.79rCSI 30.7%PRS 88.81
-
CSI 20.77rCSI 42.89%PRS 75.91
-
CSI 20.37rCSI 35.92%PRS 83.75
-
CSI 19.92rCSI 20.5%PRS 90.05
-
CSI 19.37rCSI 62.84%PRS 76.47
-
CSI 18.98rCSI 15%PRS 66.89
-
CSI 18.79rCSI 53.9%PRS 93.9
-
CSI 18.35rCSI 52.4%PRS 84.42
-
CSI 17.57rCSI 41.77%PRS 84.1
-
CSI 17.06rCSI 21.1%PRS 76.29
-
CSI 16.67rCSI 45.81%PRS 85.43
-
CSI 16.14rCSI 34.33%PRS 72.91
-
CSI 15.91rCSI 24.58%PRS 77.46
-
CSI 15.77rCSI 13.99%PRS 76.1
-
CSI 15.68rCSI 37.73%PRS 91.24
-
CSI 15.36rCSI 10.69%PRS 91.74
-
CSI 15.14rCSI 27%PRS 87.03
-
CSI 14.83rCSI 22.79%PRS 68.4
-
CSI 14.5rCSI 15.13%PRS 77.63
-
CSI 14.29rCSI 12.52%PRS 85.83
-
CSI 14.23rCSI 38.37%PRS 83.62
-
CSI 13.73rCSI 11.55%PRS 90.82
-
CSI 13.67rCSI 9.82%PRS 90.64
-
CSI 13.63rCSI 39.45%PRS 78
-
CSI 13.27rCSI 9.97%PRS 84.08
-
CSI 13.16rCSI 18.23%PRS 75.81
-
CSI 13.12rCSI 16.7%PRS 83.3
-
CSI 12.8rCSI 11.75%PRS 86.12
-
CSI 12.76rCSI 20.68%PRS 73.43
-
CSI 12.75rCSI 13.05%PRS 86.55
-
CSI 12.39rCSI 17.21%PRS 77.07
-
CSI 12.15rCSI 8.19%PRS 90.66
-
CSI 11.89rCSI 10.97%PRS 79.84
-
CSI 11.53rCSI 14.79%PRS 81.76
-
CSI 11.36rCSI 32.68%PRS 74.25
-
CSI 11.26rCSI 17.47%PRS 82.77
-
CSI 11.23rCSI 8.31%PRS 71.94
-
CSI 11.05rCSI 29.17%PRS 85.1
-
CSI 10.97rCSI 9.45%PRS 79.55
-
CSI 10.88rCSI 34.92%PRS 80.55
-
CSI 10.68rCSI 23.85%PRS 85.42
-
CSI 10.54rCSI 8.29%PRS 83.71
-
CSI 10.54rCSI 8.44%PRS 91.58
-
CSI 10.49rCSI 16.02%PRS 85.82
-
CSI 10.47rCSI 7.78%PRS 88.95
-
CSI 10.4rCSI 55.5%PRS 94.92
-
CSI 10.38rCSI 9.12%PRS 67.42
-
CSI 10.37rCSI 7.89%PRS 90.35
-
CSI 10.29rCSI 10.16%PRS 91.1
-
CSI 10.26rCSI 9.55%PRS 79.03
-
CSI 10.24rCSI 10.22%PRS 72.16
-
CSI 10.22rCSI 9.66%PRS 77.13
-
CSI 10.16rCSI 38.68%PRS 69.3
-
CSI 10.15rCSI 35.62%PRS 86.7
-
CSI 10.06rCSI 54.26%PRS 85.04
-
CSI 9.88rCSI 10.07%PRS 88.2
-
CSI 9.78rCSI 6.8%PRS 89.35
-
CSI 9.64rCSI 10.1%PRS 81.84
-
CSI 9.61rCSI 7.81%PRS 77.71
-
CSI 9.52rCSI 23.56%PRS 77.92
-
CSI 9.46rCSI 16.2%PRS 84.86
-
CSI 9.43rCSI 11.39%PRS 86.07
-
CSI 9.39rCSI 14.18%PRS 83.59
-
CSI 9.35rCSI 19.19%PRS 88.31
-
CSI 9.16rCSI 7.1%PRS 81.97
-
CSI 9.14rCSI 20.12%PRS 82.06
-
CSI 9.02rCSI 14.33%PRS 87.16
-
CSI 8.99rCSI 6.73%PRS 90.51
-
CSI 8.91rCSI 12.14%PRS 69.96
-
CSI 8.8rCSI 17.68%PRS 68.46
-
CSI 8.52rCSI 8.38%PRS 81.22
-
CSI 8.43rCSI 32.81%PRS 92.95
-
CSI 8.31rCSI 8.61%PRS 82.65
-
CSI 8.19rCSI 53.72%PRS 93.71
-
CSI 8.1rCSI 11.87%PRS 87.61
-
CSI 0.2rCSI 4.6%PRS 90.6%
-
CSI 0.3rCSI 2.0%PRS 72.3%
-
CSI 0.3rCSI 2.8%PRS 89.0%
-
CSI 0.4rCSI 8.8%PRS 87.1%
-
CSI 0.4rCSI 4.0%PRS 84.6%
-
CSI 0.4rCSI 2.9%PRS 92.5%
-
CSI 0.6rCSI 14.7%PRS 86.3%
-
CSI 0.7rCSI 4.5%PRS 83.7%
-
CSI 0.7rCSI 2.4%PRS 76.7%
-
CSI 0.8rCSI 19.5%PRS 92.2%
-
CSI 0.9rCSI 1.2%PRS 78.1%
-
CSI 0.9rCSI 2.8%PRS 62.0%
-
CSI 1.0rCSI 2.3%PRS 72.3%
-
CSI 1.2rCSI 4.9%PRS 84.1%
-
CSI 1.2rCSI 2.6%PRS 85.6%
-
CSI 1.2rCSI 8.3%PRS 85.3%
-
CSI 1.2rCSI 2.0%PRS 82.1%
-
CSI 1.3rCSI 10.1%PRS 84.2%
-
CSI 1.3rCSI 20.7%PRS 87.0%
-
CSI 1.4rCSI 3.9%PRS 85.9%
-
CSI 1.4rCSI 36.6%PRS 93.6%
-
CSI 1.5rCSI 3.5%PRS 95.7%
-
CSI 1.5rCSI 7.3%PRS 89.6%
-
CSI 1.5rCSI 6.2%PRS 86.5%
-
CSI 1.6rCSI 16.9%PRS 86.9%
-
CSI 1.6rCSI 8.6%PRS 94.8%
-
CSI 1.7rCSI 8.7%PRS 84.3%
-
CSI 1.7rCSI 3.0%PRS 77.5%
-
CSI 1.7rCSI 35.9%PRS 93.0%
-
CSI 1.7rCSI 1.6%PRS 92.0%
-
CSI 1.8rCSI 46.5%PRS 87.3%
-
CSI 1.8rCSI 20.9%PRS 93.4%
-
CSI 1.8rCSI 4.0%PRS 77.8%
-
CSI 1.8rCSI 54.8%PRS 89.4%
-
CSI 1.8rCSI 6.6%PRS 92.9%
-
CSI 2.0rCSI 3.1%PRS 78.7%
-
CSI 2.1rCSI 7.3%PRS 82.7%
-
CSI 2.1rCSI 3.7%PRS 59.6%
-
CSI 2.1rCSI 20.9%PRS 87.6%
-
CSI 2.1rCSI 3.3%PRS 82.4%
-
CSI 2.1rCSI 9.3%PRS 85.7%
-
CSI 2.3rCSI 10.8%PRS 87.3%
-
CSI 2.4rCSI 3.3%PRS 94.5%
-
CSI 2.5rCSI 2.7%PRS 83.7%
-
CSI 2.5rCSI 3.7%PRS 83.2%
-
CSI 2.6rCSI 44.8%PRS 89.0%
-
CSI 2.6rCSI 5.0%PRS 91.8%
-
CSI 2.6rCSI 3.0%PRS 82.4%
-
CSI 2.8rCSI 17.3%PRS 87.7%
-
CSI 2.8rCSI 2.2%PRS 94.1%
-
CSI 2.8rCSI 31.0%PRS 84.1%
-
CSI 2.9rCSI 5.4%PRS 86.3%
-
CSI 2.9rCSI 15.5%PRS 86.4%
-
CSI 3.0rCSI 14.7%PRS 86.2%
-
CSI 3.0rCSI 12.9%PRS 84.4%
-
CSI 3.2rCSI 4.8%PRS 75.4%
-
CSI 3.3rCSI 6.6%PRS 90.1%
-
CSI 3.4rCSI 17.2%PRS 93.4%
-
CSI 3.4rCSI 20.9%PRS 94.6%
-
CSI 3.4rCSI 9.8%PRS 85.0%
-
CSI 3.4rCSI 5.1%PRS 78.6%
-
CSI 3.5rCSI 64.8%PRS 94.3%
-
CSI 3.6rCSI 8.6%PRS 82.7%
-
CSI 3.6rCSI 12.9%PRS 95.7%
-
CSI 3.7rCSI 4.4%PRS 88.6%
-
CSI 3.7rCSI 49.2%PRS 94.2%
-
CSI 3.8rCSI 6.8%PRS 71.9%
-
CSI 3.8rCSI 7.9%PRS 66.2%
-
CSI 3.9rCSI 6.2%PRS 71.3%
-
CSI 4.0rCSI 10.5%PRS 90.2%
-
CSI 4.1rCSI 17.9%PRS 87.0%
-
CSI 4.1rCSI 5.1%PRS 79.8%
-
CSI 4.1rCSI 26.7%PRS 88.0%
-
CSI 4.2rCSI 4.9%PRS 70.6%
-
CSI 4.3rCSI 8.2%PRS 89.5%
-
CSI 4.6rCSI 6.6%PRS 90.6%
-
CSI 4.7rCSI 13.7%PRS 90.8%
-
CSI 4.7rCSI 8.5%PRS 88.8%
-
CSI 4.7rCSI 4.1%PRS 87.9%
-
CSI 4.9rCSI 3.5%PRS 81.8%
-
CSI 5.0rCSI 5.3%PRS 79.6%
-
CSI 5.0rCSI 3.7%PRS 90.5%
-
CSI 5.1rCSI 38.1%PRS 88.7%
-
CSI 5.1rCSI 7.3%PRS 79.4%
-
CSI 5.1rCSI 13.1%PRS 71.7%
-
CSI 5.2rCSI 14.6%PRS 73.5%
-
CSI 5.2rCSI 19.7%PRS 61.3%
-
CSI 5.2rCSI 8.0%PRS 86.8%
-
CSI 5.4rCSI 14.2%PRS 84.5%
-
CSI 5.4rCSI 8.6%PRS 70.2%
-
CSI 5.6rCSI 28.7%PRS 92.8%
-
CSI 5.6rCSI 4.3%PRS 81.1%
-
CSI 5.9rCSI 7.5%PRS 74.6%
-
CSI 6.1rCSI 7.4%PRS 85.0%
-
CSI 6.1rCSI 35.5%PRS 82.4%
-
CSI 6.2rCSI 28.0%PRS 94.2%
-
CSI 6.2rCSI 6.1%PRS 91.1%
-
CSI 6.3rCSI 8.4%PRS 77.3%
-
CSI 6.5rCSI 10.5%PRS 77.8%
-
CSI 6.6rCSI 8.3%PRS 93.2%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 1852624224
Symbol: IMDH2_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 2902093
Title: Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs.
PubMed ID: 2902093
PubMed ID: 1969416
Title: Two distinct cDNAs for human IMP dehydrogenase.
PubMed ID: 1969416
PubMed ID: 7999076
Title: Cloning and sequence of the human type II IMP dehydrogenase gene.
PubMed ID: 7999076
PubMed ID: 7896827
Title: Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene.
PubMed ID: 7896827
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 8098009
Title: Chromosomal localization and structure of the human type II IMP dehydrogenase gene.
PubMed ID: 8098009
PubMed ID: 7903306
Title: Characterization of human type I and type II IMP dehydrogenases.
PubMed ID: 7903306
PubMed ID: 7763314
Title: Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding.
PubMed ID: 7763314
PubMed ID: 14654843
Title: Proteomic characterization of the human centrosome by protein correlation profiling.
PubMed ID: 14654843
DOI: 10.1038/nature02166
PubMed ID: 14766016
Title: Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo.
PubMed ID: 14766016
DOI: 10.1042/bj20031585
PubMed ID: 15592455
Title: Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.
PubMed ID: 15592455
DOI: 10.1038/nbt1046
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 17496727
Title: A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity.
PubMed ID: 17496727
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19608861
Title: Lysine acetylation targets protein complexes and co-regulates major cellular functions.
PubMed ID: 19608861
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
PubMed ID: 28985504
Title: CLOCK acetylates ASS1 to drive circadian rhythm of ureagenesis.
PubMed ID: 28985504
PubMed ID: 24477477
Title: Glutamine deprivation initiates reversible assembly of mammalian rods and rings.
PubMed ID: 24477477
PubMed ID: 30293565
Title: ANKRD9 is associated with tumor suppression as a substrate receptor subunit of ubiquitin ligase.
PubMed ID: 30293565
PubMed ID: 31337707
Title: ANKRD9 is a metabolically-controlled regulator of IMPDH2 abundance and macro-assembly.
PubMed ID: 31337707
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
DOI: 10.1038/nsmb.3366
PubMed ID: 10097070
Title: Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.
PubMed ID: 10097070
Sequence Information:
- Length: 514
- Mass: 55805
- Checksum: 876BEA0EC1DDBEE9
- Sequence:
MADYLISGGT SYVPDDGLTA QQLFNCGDGL TYNDFLILPG YIDFTADQVD LTSALTKKIT LKTPLVSSPM DTVTEAGMAI AMALTGGIGF IHHNCTPEFQ ANEVRKVKKY EQGFITDPVV LSPKDRVRDV FEAKARHGFC GIPITDTGRM GSRLVGIISS RDIDFLKEEE HDCFLEEIMT KREDLVVAPA GITLKEANEI LQRSKKGKLP IVNEDDELVA IIARTDLKKN RDYPLASKDA KKQLLCGAAI GTHEDDKYRL DLLAQAGVDV VVLDSSQGNS IFQINMIKYI KDKYPNLQVI GGNVVTAAQA KNLIDAGVDA LRVGMGSGSI CITQEVLACG RPQATAVYKV SEYARRFGVP VIADGGIQNV GHIAKALALG ASTVMMGSLL AATTEAPGEY FFSDGIRLKK YRGMGSLDAM DKHLSSQNRY FSEADKIKVA QGVSGAVQDK GSIHKFVPYL IAGIQHSCQD IGAKSLTQVR AMMYSGELKF EKRTSSAQVE GGVHSLHSYE KRLF